TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Detection capacity of patient clinical status in imagery with F-MISO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of ARI
Endpoint domain: Adverse events/effects
Primary endpoint: Employed or taking steps to find a job
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Family economic hardship scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skills on maternal, newborn and child health emergency procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Overall 90-Day Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival Rate at 6 Months (OS-6)
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Rate at 12 Months (OS-12)
Endpoint domain: Mortality/survival
Primary endpoint: Geometric Mean Maximum Observed Plasma Concentration (Cmax) for Midazolam Administered Orally
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Area Under the Plasma Concentration-time Curve (AUC∞) for Midazolam Administered Orally
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Maximum Observed Plasma Concentration (Cmax) for Midazolam Administered Intravenously
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Area Under the Plasma Concentration-time Curve (AUC∞) for Midazolam Administered Intravenously
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the semaglutide plasma concentration - time curve (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Drug-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sexual Health Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental Monitoring
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sexual Communication Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ACR 20 clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respect of treatment and hygienic dietary measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Culture negative survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in corneal endothelial cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in HIV-1 RNA Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rates of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Time from Catheter Insertion to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantitative liver function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of sinus rhythm after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of post-thoracotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking test distance at six minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form-36 Health Survey (SF-36), physical functioning section
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Basic activities of daily living score (BADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Computerized Tower Of London (cTOL)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in symptoms of mental health scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of ovocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rectosigmoid perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Kinematic patterns during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematic patterns during deep knee bend
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematics patterns during going up and down stairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematics patterns during getting up from chair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of exceeding resistance criteria in H. pylori antibiotic susceptibility test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity and Specificity of salivary MMP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Behavior Change
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incorporation of StratticeTM Reconstructive Tissue Matrix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Test of Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin-periosteal depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Endothelial function (flow-mediated dilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With SARS-CoV-2 IgG Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Assessment of clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of vital signs (including blood pressure and pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of cardiac conduction intervals as assessed via 12-lead electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Documented Incident HIV Infections
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Reach Peak Concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in naming on the Boston Naming Test (BNT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Transplant/Transintrahepatic Portosystemic Shunt (TIPS) free survival
Endpoint domain: Mortality/survival
Primary endpoint: Confirmation of Prostate Cancer Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in measures of neuromuscular functions of the trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Summative and domain quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in pseudotesticular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with scrotal appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Upper Extremity Fugl Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects reporting an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in quantitative HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with suppression of HBV DNA <2000 IU/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measure specific to rotator cuff disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diameter of inferior vena cava and aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metastases progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: First occurrence of death or nonfatal myocardial infarction or nonfatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral breast tumor recurrence-free survival (IBT-RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in HCV Knowledge Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ventricular tachyarrhythmia (VT) or sudden cardiac death (SCD)
Endpoint domain: Mortality/survival
Primary endpoint: Time to onset and severity of drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and Quantity of Drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problem drinking symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (ASCo-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Rate of New Osteochondromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: appetite profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of lung tissue lesions with fibrosis and interstitial changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in QIDS-SR score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in GP-ETB scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With at Least One Solicited Injection Site Reaction or Systemic Reaction Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Time to Complete Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test of Grocery Shopping Skills
Endpoint domain: Life impact
Endpoint subdomain: Functional outcomes
Primary endpoint: Patient attendance at scheduled pain clinic appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence proportion of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: response rate of locally advanced HNSCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage reduction of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Measurements With < 15% Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Physiological Markers of Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome score International Knee Documentation committee (IKDC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional outcome score Tegner-Lysholm
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional outcome score Knee Injury and Osteoarthritis Outcome (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of correctly identified patients with tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Frequency of Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Acute Medication Intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Severe Oral Mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Gemfibrozil Area Under the Concentration vs. Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident clinical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Behavioral performance on computerized tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI data (neural activation) during behavioral task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in S-100b protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in NSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of NLDO interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Volume of Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA Level <40 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force reproduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subacromial space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased blood pressure at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distance of walk after SMWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in in vivo elastographic properties of thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Patient's satisfaction with cosmetic appearance/result of the wound
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tracer uptake in tumour lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intra-procedural or immediate post-procedure complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total incidence of fluid retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Body Weight Change After 24 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Relative Change in Body Weight After 24 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Months With Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visual Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Major Pathologic Response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Eye Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound concentration of ertapenem and meropenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of AG-120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of AG-120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of AG-120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-assessment of Functioning - Role Limitations Due to Emotional Problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Self-assessment of Functioning - Vitality
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Self-assessment of Functioning - Social Functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Fatal or non-fatal venous thromboembolism (VTE)
Endpoint domain: Mortality/survival
Primary endpoint: Fatal or non-fatal cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Hemoglobin Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood PH Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of regimen limiting toxicities (RLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number and severity of CTCAE adverse events related to study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Keratitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of subjects with clonal evolution
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of anti-SOX2 reactive T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom rate of PVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedure-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HAM-D17 scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MADRS scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IDS-SR30 scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological battery test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of primary aldosteronism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mortality before hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Time to death among survivors to hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Quantity of Paclitaxel onkovis needed per treatment cycle
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peak Plasma Concentration (Cmax) of astaxanthin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of astaxanthin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein metabolism in gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T cell reactivity to viral antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients accepting HIV test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stroke event
Endpoint domain: Mortality/survival
Primary endpoint: Change in score on a Social Anxiety Disorder rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CVR response to transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVR response to hydroxyurea therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain network of BAVMs in Geschwind's area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain network after injury of Geschwind's area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain network of the brain reorganization after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in Nasal Index Score (NIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes